Indian molecular diagnostics company making TrueNat point-of-care PCR testing devices for TB and infectious diseases.
Indian molecular diagnostics company making TrueNat point-of-care PCR testing devices for TB and infectious diseases.
Sells the small battery-run machines and then earns repeatedly on the single-use test chips each sample needs. Government health programmes, including India's TB control, are the biggest buyers and order through tenders, and the World Health Organization's endorsement of its TB test opened many overseas health programmes.
In one line: India's Cepheid equivalent for point-of-care molecular diagnostics.
Moat: narrow (IP / patents, process know-how). Proprietary battery-operated point-of-care PCR platform suited for low-resource settings, unlike lab-bound rivals.
Headquarters: Goa, India · Founded: 2001 · Employees: 2,840
Size Molbio Diagnostics (MOLBIO.NS) is an India Health Care company (Medical Specialties) with a market value of $1.85B, the 399th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,498 on 18 Nov 2026.
Growth Revenue grew 35.2% over the last twelve months (peer median +10.9%); the operating margin is 17.3% (peer median 13.6%).
Valuation It trades at 13.1× enterprise value to sales against a peer median of 4.0× (4th most expensive of 21).
Capital Return on invested capital runs 1.8 points above its cost of capital (9.4% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | ₹13.1B | ₹9.71B | ₹8.37B | ₹3.32B |
| Revenue growth | — | +35% | +16% | +152% | — |
| Gross profit | n/a | ₹6.32B | ₹4.49B | ₹3.60B | ₹882M |
| EBITDA | n/a | ₹2.63B | ₹2.35B | ₹2.15B | ₹512M |
| Net income | n/a | ₹1.45B | ₹1.40B | ₹1.02B | -₹7.26M |
| Free cash flow | n/a | -₹899M | ₹2.04B | -₹170M | ₹476M |
| Capital expenditure | n/a | ₹361M | ₹422M | ₹161M | ₹145M |
| Total debt | ₹3.90B | ₹3.46B | ₹262M | ₹1.84B | ₹1.19B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Molbio Diagnostics MOLBIO.NS | $1.85B | n/a | +35% | 17% | 13.1× | n/a |
| Danaher DHR | $161B | +34% | +6% | 21% | 7.1× | 20.8% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 4.3× | 16.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MOLBIO.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.4% | -4.4% | 9th highest of 21 |
| Distance from 52-week high | -11.2% | -25.5% | 5th highest of 21 |
| Revenue growth (TTM) | +35.2% | +10.9% | 5th highest of 21 |
| Operating margin | 17.3% | 13.6% | 7th highest of 21 |
| EV / Sales | 13.1× | 4.0× | 4th most expensive of 21 |
| ROIC minus cost of capital | +1.8 pp | -0.6 pp | 10th highest of 21 |
| EV / EBITDA | 65.4× | 15.7× | most expensive of 16 |
| Net debt / EBITDA | -0.7× | -1.0× | 7th most indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | 13.1× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 4.4× | 13.8% | +11.7% |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 3.5× | 18.3% | +14.5% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 1.6× | -1.6% | -1.0% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 5.7× | n/a | n/a |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 0.8× | -12.6% | +2.1% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 7.7× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 2.8× | 4.8% | +19.7% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 23.1× | 19.4% | +12.7% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 5.7× | 2.9% | +14.0% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 5.5× | 16.4% | +12.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 2.2× | -1.9% | +8.3% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 1.1× | 11.2% | +1.9% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | 14.6× | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 1.6× | 28.7% | +51.2% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 1.3× | n/a | n/a |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 14.6× | 12.6% | +45.4% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 3.0× | 18.0% | +34.5% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | 12.3× | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 3.0× | 16.7% | +25.8% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | 8.7× | n/a | n/a |